Antifibrosis effect of novel oridonin analog CYD0618 via suppression of the NF-κB pathway

Claire B. Cummins, Xiaofu Wang, Jimin Xu, Byron D. Hughes, Ye Ding, Haiying Chen, Jia Zhou, Ravi Radhakrishnan

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Liver fibrosis is characterized as excessive deposition of the extracellular matrix proteins, primarily by activated hepatic stellate cells (HSCs). NF-κB has been reported as one of the major mediators of HSC activation. Previously, our team reported that oridonin exhibited antihepatic fibrogenetic activity in vitro. In this study, we examined the effects of its novel derivative CYD0618 on HSC viability, apoptosis, and NF-κB signaling. Methods: Cell proliferation of activated human and rat HSC lines LX-2 and HSC-T6 was measured using Alamar Blue Assay. Apoptosis was measured by a Cell Death Detection ELISA kit. Cellular proteins were determined by Western blots and immunofluorescence. Results: CYD0618 significantly inhibited LX-2 and HSC-T6 cell proliferation in a dose-dependent manner. CYD0618 induced cell apoptosis in both cell lines. CYD0618 treatment increased cell cycle inhibitory protein p21, p27, and induced apoptosis marker cleaved poly (ADP-ribose) polymerase, while suppressing the expression of Collagen type 1. CYD0618 blocked lipopolysaccharide (LPS)-induced NF-κB p65 nuclear translocation and DNA binding activity and prevented LPS-induced NF-κB inhibitory protein IκBα phosphorylation and degradation. LPS-stimulated NF-κB downstream target cytokines IL-6 and MCP-1 were attenuated by CYD0618. Endogenous and LPS-stimulated NF-κB p65 S536 phosphorylation was inhibited by CYD0618 treatment. Conclusions: The potent antihepatic fibrogenetic effect of CYD0618 may be mediated via suppression of the NF-κB pathway.

Original languageEnglish (US)
Pages (from-to)283-292
Number of pages10
JournalJournal of Surgical Research
Volume232
DOIs
StatePublished - Dec 1 2018

Fingerprint

Hepatic Stellate Cells
Lipopolysaccharides
Apoptosis
Phosphorylation
Cell Proliferation
Cell Line
Cell Cycle Proteins
Poly(ADP-ribose) Polymerases
Extracellular Matrix Proteins
Collagen Type I
Liver Cirrhosis
Fluorescent Antibody Technique
oridonin
Interleukin-6
Cell Survival
Cell Death
Western Blotting
Enzyme-Linked Immunosorbent Assay
Cytokines
DNA

Keywords

  • Hepatic stellate cells
  • Liver fibrosis
  • NF-κB pathway
  • Oridonin
  • Therapeutics

ASJC Scopus subject areas

  • Surgery

Cite this

Antifibrosis effect of novel oridonin analog CYD0618 via suppression of the NF-κB pathway. / Cummins, Claire B.; Wang, Xiaofu; Xu, Jimin; Hughes, Byron D.; Ding, Ye; Chen, Haiying; Zhou, Jia; Radhakrishnan, Ravi.

In: Journal of Surgical Research, Vol. 232, 01.12.2018, p. 283-292.

Research output: Contribution to journalArticle

Cummins, Claire B. ; Wang, Xiaofu ; Xu, Jimin ; Hughes, Byron D. ; Ding, Ye ; Chen, Haiying ; Zhou, Jia ; Radhakrishnan, Ravi. / Antifibrosis effect of novel oridonin analog CYD0618 via suppression of the NF-κB pathway. In: Journal of Surgical Research. 2018 ; Vol. 232. pp. 283-292.
@article{658b30d6366b4b37bca7cde79c89c517,
title = "Antifibrosis effect of novel oridonin analog CYD0618 via suppression of the NF-κB pathway",
abstract = "Background: Liver fibrosis is characterized as excessive deposition of the extracellular matrix proteins, primarily by activated hepatic stellate cells (HSCs). NF-κB has been reported as one of the major mediators of HSC activation. Previously, our team reported that oridonin exhibited antihepatic fibrogenetic activity in vitro. In this study, we examined the effects of its novel derivative CYD0618 on HSC viability, apoptosis, and NF-κB signaling. Methods: Cell proliferation of activated human and rat HSC lines LX-2 and HSC-T6 was measured using Alamar Blue Assay. Apoptosis was measured by a Cell Death Detection ELISA kit. Cellular proteins were determined by Western blots and immunofluorescence. Results: CYD0618 significantly inhibited LX-2 and HSC-T6 cell proliferation in a dose-dependent manner. CYD0618 induced cell apoptosis in both cell lines. CYD0618 treatment increased cell cycle inhibitory protein p21, p27, and induced apoptosis marker cleaved poly (ADP-ribose) polymerase, while suppressing the expression of Collagen type 1. CYD0618 blocked lipopolysaccharide (LPS)-induced NF-κB p65 nuclear translocation and DNA binding activity and prevented LPS-induced NF-κB inhibitory protein IκBα phosphorylation and degradation. LPS-stimulated NF-κB downstream target cytokines IL-6 and MCP-1 were attenuated by CYD0618. Endogenous and LPS-stimulated NF-κB p65 S536 phosphorylation was inhibited by CYD0618 treatment. Conclusions: The potent antihepatic fibrogenetic effect of CYD0618 may be mediated via suppression of the NF-κB pathway.",
keywords = "Hepatic stellate cells, Liver fibrosis, NF-κB pathway, Oridonin, Therapeutics",
author = "Cummins, {Claire B.} and Xiaofu Wang and Jimin Xu and Hughes, {Byron D.} and Ye Ding and Haiying Chen and Jia Zhou and Ravi Radhakrishnan",
year = "2018",
month = "12",
day = "1",
doi = "10.1016/j.jss.2018.06.040",
language = "English (US)",
volume = "232",
pages = "283--292",
journal = "Journal of Surgical Research",
issn = "0022-4804",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Antifibrosis effect of novel oridonin analog CYD0618 via suppression of the NF-κB pathway

AU - Cummins, Claire B.

AU - Wang, Xiaofu

AU - Xu, Jimin

AU - Hughes, Byron D.

AU - Ding, Ye

AU - Chen, Haiying

AU - Zhou, Jia

AU - Radhakrishnan, Ravi

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Background: Liver fibrosis is characterized as excessive deposition of the extracellular matrix proteins, primarily by activated hepatic stellate cells (HSCs). NF-κB has been reported as one of the major mediators of HSC activation. Previously, our team reported that oridonin exhibited antihepatic fibrogenetic activity in vitro. In this study, we examined the effects of its novel derivative CYD0618 on HSC viability, apoptosis, and NF-κB signaling. Methods: Cell proliferation of activated human and rat HSC lines LX-2 and HSC-T6 was measured using Alamar Blue Assay. Apoptosis was measured by a Cell Death Detection ELISA kit. Cellular proteins were determined by Western blots and immunofluorescence. Results: CYD0618 significantly inhibited LX-2 and HSC-T6 cell proliferation in a dose-dependent manner. CYD0618 induced cell apoptosis in both cell lines. CYD0618 treatment increased cell cycle inhibitory protein p21, p27, and induced apoptosis marker cleaved poly (ADP-ribose) polymerase, while suppressing the expression of Collagen type 1. CYD0618 blocked lipopolysaccharide (LPS)-induced NF-κB p65 nuclear translocation and DNA binding activity and prevented LPS-induced NF-κB inhibitory protein IκBα phosphorylation and degradation. LPS-stimulated NF-κB downstream target cytokines IL-6 and MCP-1 were attenuated by CYD0618. Endogenous and LPS-stimulated NF-κB p65 S536 phosphorylation was inhibited by CYD0618 treatment. Conclusions: The potent antihepatic fibrogenetic effect of CYD0618 may be mediated via suppression of the NF-κB pathway.

AB - Background: Liver fibrosis is characterized as excessive deposition of the extracellular matrix proteins, primarily by activated hepatic stellate cells (HSCs). NF-κB has been reported as one of the major mediators of HSC activation. Previously, our team reported that oridonin exhibited antihepatic fibrogenetic activity in vitro. In this study, we examined the effects of its novel derivative CYD0618 on HSC viability, apoptosis, and NF-κB signaling. Methods: Cell proliferation of activated human and rat HSC lines LX-2 and HSC-T6 was measured using Alamar Blue Assay. Apoptosis was measured by a Cell Death Detection ELISA kit. Cellular proteins were determined by Western blots and immunofluorescence. Results: CYD0618 significantly inhibited LX-2 and HSC-T6 cell proliferation in a dose-dependent manner. CYD0618 induced cell apoptosis in both cell lines. CYD0618 treatment increased cell cycle inhibitory protein p21, p27, and induced apoptosis marker cleaved poly (ADP-ribose) polymerase, while suppressing the expression of Collagen type 1. CYD0618 blocked lipopolysaccharide (LPS)-induced NF-κB p65 nuclear translocation and DNA binding activity and prevented LPS-induced NF-κB inhibitory protein IκBα phosphorylation and degradation. LPS-stimulated NF-κB downstream target cytokines IL-6 and MCP-1 were attenuated by CYD0618. Endogenous and LPS-stimulated NF-κB p65 S536 phosphorylation was inhibited by CYD0618 treatment. Conclusions: The potent antihepatic fibrogenetic effect of CYD0618 may be mediated via suppression of the NF-κB pathway.

KW - Hepatic stellate cells

KW - Liver fibrosis

KW - NF-κB pathway

KW - Oridonin

KW - Therapeutics

UR - http://www.scopus.com/inward/record.url?scp=85049777640&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049777640&partnerID=8YFLogxK

U2 - 10.1016/j.jss.2018.06.040

DO - 10.1016/j.jss.2018.06.040

M3 - Article

VL - 232

SP - 283

EP - 292

JO - Journal of Surgical Research

JF - Journal of Surgical Research

SN - 0022-4804

ER -